In a pivotal phase 2 trial, elranatamab, a bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3, had a confirmed objective response rate of 61% in patients with relapsed or refractory multiple myeloma who had not previously received BCMA-directed therapy.

This Review outlines three ‘grand challenges’ to protect and promote health in the face of climate change, and discusses the role of the health community in driving change within and beyond the health sector.

A phase I trial of cerebellar deep brain stimulation to enhance chronic post-stroke motor rehabilitation supports the safety and feasibility of the approach while providing encouraging evidence of motor improvements.

Using extracted images and related labels from pathology-related tweets, a model is trained to associate tissue images and text and approaches state-of-the-art performance in clinically relevant tasks, such as tissue classification.

Patients with stage 4 or unresectable stage 3 melanoma refractory to first-line anti-programmed death protein 1 (PD-1) or anti-programmed cell death 1 ligand 1 have longer progression-free survival when treated with a combination of anti-cytotoxic T-lymphocyte protein 4 (CTLA-4) and anti-PD-1 versus anti-CTLA-4 alone.

This is a post hoc 18-month follow-up analysis of the CRB-401 trial, testing idecabtagene vicleucel (ide-cel, bb2121) in relapsed and refractory multiple myeloma, and reports sustained safety and clinical efficacy, which correlates with T cell phenotypes.

In a pivotal phase 2 trial, elranatamab, a bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3, had a confirmed objective response rate of 61% in patients with relapsed or refractory multiple myeloma who had not previously received BCMA-directed therapy.

A phase I trial of cerebellar deep brain stimulation to enhance chronic post-stroke motor rehabilitation supports the safety and feasibility of the approach while providing encouraging evidence of motor improvements.

In a preclinical study, the delivery of an AAV-based gene therapy encoding GDNF in the brain prevented the return to alcohol use behaviors in a non-human primate model.

Researchers have identified a naturally occurring, non–genetically modified symbiotic bacterium that inhabits the gut of mosquitoes and prevents Plasmodium transmission.

Twenty years after completion of the Human Genome Project, genetics is rapidly being integrated into everyday clinical practice. But in this era of genomic revolution, genetically trained teams of healthcare workers are needed to optimize delivery of patient care.

AstraZeneca has introduced digital health solutions into clinical trials, demonstrating improved patient experience, accelerated timelines and reduced costs.

Nature Medicine explores the latest translation and clinical research news, with a phase 3 trial from Merck and Moderna testing mRNA-4157 combined with pembrolizumab in melanoma.

In a prospective study, artificial intelligence–assisted mammography screening had accuracy comparable to that of standard double reading — and substantially reduced radiologists’ workloads.